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INTRODUCTION 
 
The APOE (Apolipoprotein E) gene has three major 
isoforms named APOE2, APOE3, and APOE4. These 
isoforms are coded by e2, e3, and e4 alleles, which are 
the haplotypes of the single nucleotide polymorphisms 
(SNPs), rs429358 and rs7412 on chromosome 19 (T-T, 
C-T, and C-C, respectively). e2 is associated with 
decreasing apolipoprotein E, followed by e3 and then 
e4. The allele-specific, isoform difference gives the 
variation in domain interaction, protein stability, and 
protein folding, which influence various pathologies [1, 
2], where APOE plays the role of shuttling cholesterol 
and other lipids between cells in the periphery and the 
central nervous system [3]. 
In European-ancestry populations, the frequencies of e2, 
e3, and e4 are approximately 8%, 78%, and 13%, 
similarly in men and in women [4]. The majority of the 
population are e3e3 homozygotes (63%), followed by 
e4e3 (19%) and then e2e3 (13%) [4]. While the e3 
allele is the most abundant allele, e4 is the ancestral 
allele and e2 emerged after e3 [5]. The e2 allele is the 
youngest (8,000 years ago from east Asia) but under 
positive selection, expected to have strong evolutionary 
advantages [5]. 
 
Previous studies have shown that the risk of Alzheimer’s 
disease in e4e4 homozygotes (OR=14.9, 95% CI=10.8 to 
20.6) is more than double the risk of e4e3 (OR=3.2, 95% 
CI=2.8 to 3.8) [6]. Assuming a similar pattern, we 
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ABSTRACT 
 
The Apolipoprotein E (APOE) e4 allele is associated with reduced longevity and increased Coronary Artery Disease 
(CAD) and Alzheimer’s disease, with e4e4 having markedly larger effect sizes than e3e4. The e2 longevity 
promoting variant is less studied. We conducted a phenome-wide association study of ApoE e2e3 and e2e2 with 
aging phenotypes, to assess their potential as targets for anti-aging interventions. Data were from 379,000 UK 
Biobank participants, aged 40 to 70 years. e2e3 (n=46,535) had mostly lower lipid-related biomarker levels 
including reduced total and LDL-cholesterol, and lower risks of CAD (Odds Ratio=0.87, 95% CI: 0.83 to 0.90, 
p=4.92×10-14) and hypertension (OR=0.94, 95% CI: 0.92 to 0.97, p=7.28×10-7) versus e3e3. However, lipid changes 
in e2e2 (n=2,398) were more extreme, including a marked increase in triglyceride levels (0.41 Standard Deviations, 
95% CI: 0.37 to 0.45, p=5.42×10-92), with no associated changes in CAD risks. There were no associations with 
biomarkers of kidney function. The effects of both e2e2 and e2e3 were minimal on falls, muscle mass, grip 
strength or frailty. In conclusion, e2e3 has protective effects on some health outcomes, but the effects of e2e2 are 
not similar, complicating the potential usefulness of e2 as a target for anti-aging intervention. 
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hypothesized that the effect of e2e2 is much stronger 
than that of e2e3 on aging phenotypes and we aimed to 
characterize individual genotypic effects. e2 has been 
associated with longevity and reduced risks of 
Alzheimer’s disease, dementia with Lewy bodies, and 
cardiovascular diseases (coronary artery disease, 
myocardial infarction (MI), ischemic stroke). e2 has also 
been associated with increased high-density lipoprotein 
cholesterol (HDL), and decreased total cholesterol and 
low-density lipoprotein (LDL) cholesterol [1, 3, 7]. The 
association between e2 and longevity has been robustly 
replicated across studies [3, 7–9] and may be partly 
attributed to negative associations with diseases and 
conditions. However, e2 has been linked to diseases 
including age-related macular degeneration (AMD)  
[10, 11], renal disease [12], lipid metabolism disorders 
(type III hyperlipidemia, high triglycerides or 
hypertriglyceridemia), and cerebrovascular diseases 
(cerebral amyloid angiopathy that frequently causes 
lobar hemorrhagic stroke) [3]. All of these detrimental 
effects need to be considered to leverage the efficacy of 
e2-based therapeutics. 
 
In general, drug targets with genetic evidence support 
are more likely to succeed in human trials [13]. 
Moreover, associations between e2 and multiple aging 
traits including longevity suggest that if the underlying 
shared aging pathways were to be targeted, such an 
approach may delay the onset of multiple diseases, 
consistent with the geroscience hypothesis [14]. To 
characterize e2 in aging, we conducted a phenome-wide 
association study to associate ApoE genotypes to a 
variety of aging traits in UK Biobank, with the focus on 
e2e2 and e2e3. The UK Biobank is well-suited to this 
analysis as it includes thousands of e2e2s and e2e3s and 
a wealth of baseline measures plus updated mortality 
and disease diagnoses. 
 
RESULTS 
 
Of 379,703 unrelated, European-descent participants 
(Table 1), 54% were women (n=204,726). The mean age 
at recruitment was 56.7 years (SD=8.0). Participants 
were followed to death or the last update of survival 
(Feb 15, 2018), with the mean follow-up time of 9.4 
years (SD=1.2). During follow-up, 15,439 participants 
died and the mean age at death was 67.3 years (SD=7.0). 
The ApoE genotype distribution was similar to that in 
the general white population. 2,398 participants were 
e2e2 homozygotes and the sample size of e2e3 was 
46,525. e1e2 and e1e4 (n=18 in total) were too few to 
study; thus, were excluded from analyses. A summary of 
studied aging associated biomarkers, diagnoses, plus 
chronic pain, functional measures and frailty (here 
termed ‘aging traits’) for separate ApoE genotypes is 
provided in Supplementary Table 1. 
The focus of this study is on e2e3 and e2e2; however, 
all the associations between ApoE genotypes and aging 
traits including those with e4 genotypes are presented in 
Supplementary Table 2. 
 
Biomarkers 
 
In Figure 1, we highlight the associations with biomarkers 
that reached the Bonferroni-adjusted significance level of 
5% and showed a 0.1 SD or larger mean difference 
between e2e2 or e2e3 and e3e3. Compared to e3e3, e2e2 
tended to be more associated than e2e3 with biomarkers 
associated with CAD. Both had lower mean total 
cholesterol (-0.78 SD in e2e2, p=1.56×10-314 versus -0.33 
SD in e2e3, p<1×10-323), LDL cholesterol (-1.12 SD in 
e2e2, p<1×10-323 versus -0.43 SD in e2e3, p<1×10-323), 
lipoprotein A (-0.40 SD in e2e2, p=4.58×10-62 versus -
0.10 SD in e2e3, p=1.41×10-61), and apolipoprotein B  
(-1.99 SD in e2e2, p<1×10-323 versus -0.56 SD in e2e3, 
p<1×10-323), plus higher apolipoprotein A1 (0.13 SD in 
e2e2, p=8.37×10-11 versus 0.11 SD in e2e3, p=1.51× 
10-104), all associated with lower risks of CAD. e2e2 and 
e2e3, however, had higher mean triglycerides (0.41 SD in 
e2e2, p=5.42×10-92 versus 0.11 SD in e2e3, p=1.04× 
10-97), which is associated with higher risks of CAD. 
 
e2e2 and e2e3 were associated with lower albumin and 
higher direct bilirubin and alkaline phosphatase, but the 
effect of e2e3 was not as striking as that of e2e2, e.g., 
0.22 SD higher in e2e2 (p=5.12×10-24) versus 0.06 SD 
higher in e2e3 compared to e3e3 for direct bilirubin 
(p=3.20×10-28). Additionally, the mean vitamin level of 
e2e2 was higher than that of e3e3 by 0.1 SD. e3e3 and 
other ApoE genotypes shared similar vitamin D levels. 
 
There were also associations with various hematology 
measures (Figure 2 and Supplementary Table 2), 
including on reticulocyte numbers, with e2e2 being 
associated with much larger effects than of e2e3. 
Compared to e3e3, e2e2 had 0.22 SD lower mean 
reticulocyte count (p=7.90×10-27), 0.30 SD lower high 
light scatter reticulocyte count (p=3.78×10-47), 0.31 SD 
lower immature reticulocyte fraction (p=3.07×10-50), and 
0.09 SD higher mean reticulocyte volume (p=8.46×10-6). 
e2e2 also had 0.43 SD higher red cell distribution width 
(RDW) than e3e3 (p=2.16×10), 0.14 SD lower mean 
corpuscular hemoglobin (p=5.84×10-12), 0.12 SD lower 
mean corpuscular volume (p=1.51×10-9), 0.11 SD higher 
mean platelet volume (p=4.97×10-8), and 0.13 SD higher 
mean sphered cell volume (p=2.12×10-10). 
 
Disease outcomes 
 
The results for diseases with ~80% power or higher to 
detect odds ratios approximately 1.2 and 1.22 comparing 
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Table 1. Included participant characteristics. 
Variable Mean ± SD or frequency (%) 
Sex (=female) 204,736 (54%) 
Age at recruitment (years) 56.7 ± 8.0 
Follow-up time (years) 9.4 ± 1.2 
Death status at Feb, 2018 (=dead) 15,439 (4.1%) 
Age at Death 67.3 ± 7.0 
ApoE genotype  
e1e2 3 (<0.01%) 
e1e4 15 (<0.01%) 
e2e2 2,398 (0.63%) 
e2e3 46,535 (12.26%) 
e2e4 9,490 (2.50%) 
e3e3 222,225 (58.53%) 
e3e4 90,016 (23.71%) 
e4e4 9,021 (2.38%) 
 
e2e3, and e2e2 to e3e3 are presented in Figure 3. All the 
disease association results can be found in 
Supplementary Table 2. CAD and hypertension were 
the two significant diseases with e2e2 and/or e2e2 effect 
compared to e3e3 at the 5% Bonferroni-adjusted level. 
e2e3 had a lower risk of hypertension than e3e3 
(OR=0.94, 95% CI: 0.92 to 0.97, p=7.28×10-7) but the 
protective effect was reduced in e2e2 (OR=1.01, 95% 
CI: 0.92 to 1.10, p=0.911). Similarly, e2e3 
heterozygotes were protected from CAD but the 
association was not seen with e2e2: the odds ratio for 
CAD was 0.87 (95% CI: 0.83 to 0.90, p=4.92×10-14) 
comparing e2e3 to e3e3 and was 1.04 (95% CI: 0.90 to 
1.19, p=0.635) comparing e2e2 to e3e3. 
 
 
 
Figure 1. Significant associations between e2e2 or e2e3 and biomarkers at the Bonferroni-corrected level of 5% 
(*p<0.05/106). 
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Figure 2. Significant associations between e2e2 or e2e3 and hematological measures at the Bonferroni-corrected level of 5% 
(*p<0.05/106). 
 
 
 
Figure 3. Associations between e2 (e2e2 or e2e3) and primary disease outcomes. Note: Traits labelled with an asterisk if significant 
at the Bonferroni-corrected level of 5% (*p<0.05/106). 
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We found no associations between e2e3 or e2e2 and 
renal failure or two kidney function biomarkers, 
creatinine and cystatin (Supplementary Table 2). 
Similarly, e2e3 or e2e2 was not associated with AMD 
and dementia. 
 
Chronic pain, cognitive function, physical measures 
and mortality 
 
e2e3 or e2e2 was not significantly associated with 
chronic pain, cognitive measures, and physical 
measures except body mass index (BMI). The mean 
BMI was 0.07 SD (95% CI: 0.03 to 0.11, p=0.001) 
higher in e2e2 than in e3e3 (Figure 4), oppositely 
associated with e4 (Supplementary Table 2). The hazard 
ratio of death during follow-up in participants 
comparing e2e3 to e3e3 was 0.96 (95% CI: 0.91 to 1.01, 
p=0.116) and that comparing e2e2 to e3e3 was 1.06 
(95% CI: 0.87 to 1.30, p=0.532) (Figure 5). 
 
DISCUSSION 
 
Analyses of ApoE e2 have reported encouraging 
findings of associations with longevity, in studies of 
parents and in centenarians [9, 15]. However, there has 
been little data on the effects of ApoE e2e2 and e2e3 
separately, perhaps because the e2e2 type is relatively 
rare. In this large cohort analysis, we conducted a 
phenome-wide association study to test associations of 
the ApoE genotypes with a wide range of aging relevant 
traits. As ApoE effects could constitute potential 
treatment targets in aging, understanding their impacts 
on various aspects of aging is important, including 
whether e2e2 has a more powerful anti-aging effect than 
e2e3. We found marked reductions in total and LDL 
cholesterol and reductions in CAD risk in e2e3 only. 
However, associations for e2e2 included a marked 
increase in triglyceride and RDW levels and an increase 
in BMI (0.07 SD, 95% CI: 0.03 to 0.11, p=0.001), with 
no association with CAD (OR=1.04, 95% CI: 0.90 to 
1.19, p=0.635). We also found minimal associations for 
both e2e3 and e2e2 with the studied aging outcomes, 
with only a small effect on Rockwood frailty (i.e., 49-
item frailty) counts. The association with participant 
mortality in e2e3 trended in the protective direction but 
did not reach statistical significance, likely due to the 
limited follow-up thus far. 
 
e2e2 had much lower apolipoprotein B, LDL 
cholesterol, total cholesterol, and lipoprotein A, and 
reticulocyte counts but higher apolipoprotein A1 and 
markedly higher triglycerides and RDW levels than 
e3e3. A similar pattern was found in e2e3 but the effect 
sizes were mostly much smaller. Several of these lipid 
changes are linked to CAD risk. The associations 
between CAD and LDL cholesterol, lipoprotein A, 
triglycerides, and reticulocyte count are likely to be 
causal based on the Mendelian randomization results 
[16–18], in which genetic variants associated with each 
risk factor were used to estimate associations with CAD 
 
 
 
Figure 4. Associations between e2e2 or e2e3 and physical measures, cognitive function, and a 49-item frailty (*<0.05/106). 
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to minimize confounding and avoid reverse causation. 
While the lower total and LDL-cholesterol are 
associated with lower CAD risk, the opposite is true for 
the triglyceride findings, especially the markedly higher 
triglyceride levels seen in e2e2, perhaps explaining the 
discordance in findings of e2e3 and e2e2 for CAD. The 
95% confidence intervals for ORs of CAD comparing 
e2e2, and e2e3 to e3e3 indicate that the two ORs are 
quite different despite a minimal overlap: e2e3 is 
protective for CAD (OR=0.87, 95% CI: 0.83 to 0.90) 
but there was no association between e2e2 and CAD 
(OR=1.04, 95% CI: 0.90 to 1.19), with the point 
estimate trending in the opposite direction and the 
confidence intervals excluding a larger protective effect 
on CAD than seen in e2e3. Similarly, only e2e3 is 
protective for hypertension, but the confidence interval 
for the e2e2 estimate was wide and mostly right to that 
of e2e3, suggesting a less protective effect. 
 
In 2012, the FDA warned that statin use may cause 
cognitive side effects based on post-marketing reports. 
However, a large randomized clinical trial of evolocumab 
to treat hyperlipidemia in statin users didn’t show a 
statistical difference in cognitive decline between the 
treatment and placebo groups [19]. A Mendelian 
randomization study also showed no evidence for a 
causal relationship between low LDL and dementia via 
genetic variation of LDL drug targets, PCSK9 and 
HMGCR [20]. We found that e2 was strongly associated 
with lower LDL levels. There was no evidence 
suggesting that e2e2 or e2e3 was associated with 
dementia, but this analysis was under-powered. A recent 
study confirmed the protective effect of e2, substantially 
increased from e2e3 (OR=0.39, 95% CI: 0.30 to 0.50) to 
e2e2 (OR=0.13, 95% CI: 0.05 to 0.36) [21], which 
suggests that lower LDL is associated with reduced risk 
of Alzheimer’s disease through e2-related mechanisms. 
The hazard ratio for participant death in this relatively 
young cohort was 0.96 (95% CI: 0.91 to 1.01) 
comparing e2e3 to e3e3, i.e., trending toward lower 
mortality but not reaching statistical significance. The 
association between e2e2 and mortality was 
inconclusive due to a small sample size. A metaanalysis 
combing four European longevity cohorts [16] showed 
that e2e3 was associated with increased parental 
extreme longevity (top 1% survival in the 1900 US birth 
cohort) (OR=1.34, 95% CI: 1.21 to 1.47) and the odds 
ratio comparing e2e2 to e3e3 was 1.26 (95% CI: 0.80 to 
1.99). Also, the e2 determined allele of rs7412 was 
increasingly associated with extreme longevity [9], 
which implies the association between e2 and extreme 
longevity in parents as parents of participants with any 
e2 allele are more likely to have e2 alleles than parents 
of e3e3 participants. However, the association between 
e2e3 or e2e2 genotypes of participants and parental 
lifespan or longevity doesn’t imply the same association 
in parents. Most parents of e2e2 participants are likely 
e2e3 heterozygotes and several parental mating 
combinations can lead to e2e3 offspring. Parental 
lifespan and longevity outcomes therefore were not 
included as the main purpose of this study is to separate 
e2e2 and e2e3 associations with aging traits. 
 
While associations between e2 and renal disease were 
previously reported, e2e3 or e2e2 was not associated 
with renal failure and two kidney function biomarkers, 
creatinine and cystatin (Supplementary Table 2). 
Similarly, e2e3 or e2e2 was not associated with AMD or 
dementia. It should be cautioned that the two conditions 
were rare in the UK Biobank and were underpowered to 
detect odds ratios ≤ 1.2 (Supplementary Table 1). With a 
longer follow-up, more cases may be available to retest 
the associations. However, we did find associations 
between e4 and dementia, where the ORs comparing 
 
 
 
Figure 5. Associations between e2e2 or e2e3 and parent, chronic pain, and physical measures (*p<0.05/106). 
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e3e4, and e4e4 to e3e3 were 2.49 (95% CI: 2.24 to 2.78) 
and 7.77 (95% CI: 6.61 to 9.13), respectively. 
 
The limitations of this study include UK Biobank 
selection biases, which may impact the ApoE genotype 
and aging trait association if the selection into the study 
is substantially associated with the aging trait [22]: such 
biases are likely to be modest given that ages at 
recruitment were 40 to 70 years old. Additionally, the 
presence or absence of disease was determined based on 
participant-reported doctor diagnoses and records 
during hospitalization, and the absence of primary care 
data in this analysis means that disease diagnoses are 
likely to be underestimated. Also, some participants 
were not old enough to develop late-onset diseases. As 
the sensitivity is not 100 percent, the odds ratio 
estimates are likely to be generally biased towards the 
null [23]. 
 
In conclusion, ApoE e2e3 was associated with reduced 
total and LDL cholesterol, and reduced risks of CAD 
and hypertension. e2e3 associations with aging 
measures such as frailty were modest. However, 
associations with e2e2 included increased triglyceride 
levels, increased BMI and no associations with CAD or 
aging measures. Overall, our results support that e2 is a 
potential anti-aging target but any intervention needs to 
take account our findings that e2e3 is likely more 
favorable than e2e2 for health outcomes in older 
groups. 
 
MATERIALS AND METHODS 
 
UK Biobank recruited over 500,000 participants aged 
40-70 years from 2006 to 2010. A wide range of genetic 
and phenotypic data were collected at recruitment 
(baseline) and mortality and disease diagnoses were 
updated through linkages to death certificates, cancer 
registry and hospital admission records [24, 25]. 
 
The DNA from blood samples was genotyped using 
Affymetrix UK BiLEVE Axiom array for the first 
~50,000 participants and Affymetrix UK Biobank 
Axiom array for the rest of the cohort - the two arrays 
sharing over 95% marker content [25]. The two ApoE 
isoform coding SNPs, rs429358 and rs7412, on 
chromosome 19, were actually genotyped and the 
participant genotypes at these two locations were used to 
determine ApoE genotypes. 
 
Included samples 
 
To avoid genetic confounding, we analyzed European-
descent participants (n=451,367, ~90% of the cohort), 
identified using genetic principal components analysis 
in detail in Thompson et al. [26]. One in third-degree or 
closer pairs were removed, leaving a total of 379,703, 
where the relatedness was determined based on pairwise 
kinship coefficients, calculated using genome-wide SNP 
data by the KING software [27]. 
 
Aging-related outcomes 
 
We classified aging-related outcomes into five 
categories: 1) biomarkers, 2) diseases and chronic pain, 
3) mortality, 4) cognitive function, and 5) physical 
measures. Survival data were updated to Feb 15, 2018 
and disease diagnoses to March 31, 2017. Others were 
surveyed or measured at recruitment/baseline. 
 
Biomarkers 
 
A panel of biomarkers from blood samples at baseline 
were collected including hematological measures (e.g., 
white blood count, red blood cell count, and 
hemoglobin concentration), prognostic biomarkers 
(e.g., lipids for vascular disease, sex hormones for 
cancer), diagnostic biomarkers (e.g., HbA1c for 
diabetes and rheumatoid factor for arthritis), and 
biomarkers to characterize phenotypes that are not well 
assessed (e.g., biomarkers for renal and liver function). 
The full lists including technical details can be 
downloaded from the links [28, 29]. Each was 
transformed by the rank-based inverse normal 
transformation, followed by the z-transformation to 
correct distribution skewness and to unify the scale 
across traits. 
 
Diseases and chronic pain 
 
Disease diagnoses were either self-reported at the 
baseline assessment and verified by a trained nurse 
during the verbal interview, or from the hospital 
admission data (HES, hospital episode statistics, 
covering the period 1996 to March 31, 2017) or the 
cancer registry. We combined prevalent and incident 
cases for the analysis of ApoE genotype associations 
with likelihood of disease. A complete list of 
International Classification of Disease tenth revision 
(ICD-10) diagnosis codes used in this study is included 
in Supplementary Table 3. 
 
Depression and chronic pain at baseline were assessed 
by survey questions to identify those with a localized 
pain for 3 months or longer (knee pain 3+ months, back 
pain 3+ months, and hip pain 3+ months) and those with 
depressed mood for several days or more in the past two 
weeks. Additionally, we derived a 49-item frailty index 
[30] mostly based on diseases and pains considering 60 
and older only (not sensible to the middle aged), and 
applied log+1 transformation to correct distribution 
skewness. 
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Mortality 
 
The death status was determined using the death 
certificate data, where age at death was calculated by 
date of death minus date of birth in years. For analytical 
purpose, we also calculated the survival time to the last 
follow up, which was Feb 15, 2018, for alive participants 
then. 
 
Cognitive function 
 
We selected two cognitive function measures from 
touch screen tests at baseline that covered the majority 
of participants, i.e., reaction time and visual memory 
errors. The reaction time was measured as the average 
time used to correctly identify a match in a symbol 
match game similar to the snap card game. The visual 
memory errors was measured as the number of errors 
that a participant made to complete a pairs matching 
task where 6 pairs of cards were presented for 3 seconds 
beforehand. Each was log transformed to correct 
skewness of the distribution. The visual memory errors 
were right shifted by 1 before the transformation to 
avoid infinite values from zero visual memory errors. 
 
Physical measures 
 
In baseline physical measures, we included body mass 
index (BMI), systolic and diastolic blood pressures, any 
falls in the last year, heel bone mineral density (BMD), 
lung function measures of FEV1 (forced expiratory 
volume in 1 second), FVC (forced vital capacity), and 
FEV1/FVC ratio, Fried frailty (frail or not frail), 
skeletal muscle mass index [31], and maximal hand grip 
strength. Any falls in the last year and some elements to 
derive the Fried frailty were assessed by survey 
questions. Other measurements were performed at the 
assessment centers when participants were recruited. 
 
Heel bone mineral density in grams/cm2 was estimated 
based on the Quantitative Ultrasound Index through the 
calcaneus. The spirometry test was performed using a 
Vitalograph Pneumotrac 6800 that analyzed 2-3 blows 
of participants. The Fried frailty [32] was derived using 
participants aged 60 and older at baseline where the 
frailty status was confirmed if three or more of the 
conditions were met, 1) self-reported weight loss 
(yes/no, based on a survey question to ask weight 
change compared to one year ago), 2) exhaustion 
(yes/no, based on a survey question to ask frequency of 
feeling tired or having little energy over the past two 
weeks), 3) self-reported slow walking pace (yes/no, 
based on a survey question to ask usual walking pace: 
slow if less than 3 miles per hour), 4) lowest 20% of 
hand grip strength in the same sex group (yes/no), 5) 
lowest 20% of physical activity in the same sex group 
(yes/no), by the short version of International Physical 
Activity Questionnaire (IPAQ) [33]. 
 
The maximal hand grip strength of both hands was 
measured using a Jamar J00105 hydraulic hand 
dynamometer. The skeletal muscle mass was measured 
by the skeletal muscle index (SMI) defined by Janssen 
et al. [31], 
 
2/SMI SMM Ht  
 
with height (Ht) in meters and the skeletal muscle mass 
(SMM) defined as 
 
2( / ) 0.401 ( 3.825)
( ( 0.071)) 5.102
SMM Ht R gender
age
   
   
 
 
where the Bioelectrical Impedance Analysis resistance 
(R) in ohms for the whole body was taken by a Tanita 
BC418MA body composition analyzer; gender was 1 
for men and 0 for women and age was measured in 
years. 
 
Statistical analysis 
 
Aging-related outcomes including time-to-event 
(survival), continuous, and binary variables were 
modelled for associations with ApoE genotypes using 
Cox regression, linear regression, and logistic regression 
models. Prior to association analyses, continuous 
variables were log-transformed (cognitive function 
measures and 49-item frailty) or transformed by the 
rank-based inverse normal transformation (biomarkers) 
to correct distribution skewness and further z-
transformed so that magnitude of mean differences by 
genotype between traits are comparable. Each ApoE 
genotype (e2e2, e2e3, e3e4, or e4e4) was compared with 
e3e3, adjusted for age at baseline (outcomes measured at 
baseline) or age at the last update (survival and disease 
outcomes), sex, assessment center, genotyping array 
type, and the first five genetic principal components. We 
highlighted associations with p-values significant at the 
Bonferroni-adjusted level (p<0.05/106) for the null 
hypothesis of no e2e3 or e2e2 effect. All the statistical 
analyses were performed in R version 3.4.1. 
 
Power analysis 
 
To estimate power for continuous traits, we assumed 
that the three genotype groups e3e3, e2e3, and e2e2 
share the same standard deviation for a trait. Given the 
sample sizes that we have for the three ApoE genotypes, 
the power to detect a 0.05 standard deviation (SD) mean 
difference between e3e3 and e2e3 or a 0.1 SD mean 
difference between e3e3 and e2e2 using an ANOVA F-
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test at the Bonferroni-adjusted significance level 
(p<0.05/106), is presented in Supplementary Table 1. 
Most continuous traits have over 99% power to detect 
the above differences, except oestradiol (65%) and 
rheumatoid factor (27%). 
 
To estimate power for binary outcomes, we assumed a 
multiplicative e2 effect and we aimed to detect the 
relative risk of 1.2 comparing e2e3 to e3e3 and (1.2)2 
comparing e2e2 to e3e3, approximately equivalent to 
the odds ratios from a logistic regression model as the 
prevalence is low (<0.1). Given the sample sizes that we 
have for e3e3, e2e3, and e2e2, the power to reject the 
null hypothesis (p<0.05/106) that both relative risks are 
1, is provided in Supplementary Table 1. We focus on 
disease outcomes with ~80% or higher power, with 
melanoma cancer (79% power) and traits with better 
power referred to as “primary” and the rest are 
considered “secondary”. 
 
Age at death was the only survival outcome in this study, 
with death status and age at the last follow-up 
information. For convenience, we approximately 
calculated the power using death status only as a binary 
outcome, which should be similar to that of the survival 
outcome as the death rate is low. We found in actual data 
analyses that the hazard ratio of death comparing e2e3 or 
e2e2 to e3e3 (see the Results section) was very similar to 
the corresponding odds ratio (results not shown). 
 
CONFLICTS OF INTEREST 
 
No conflicts of interest to disclose 
 
FUNDING 
 
This research was funded by the National Institute on 
Aging (R21AG060018) and conducted using the UK 
Biobank resource, under application 14631. UK 
Biobank received an approval from the UK Biobank 
Research Ethics Committee (REC) (REC reference 
11/NW/0382). All the participants provided written 
informed consent to participate in the study and for their 
data to be used in future research. 
 
REFERENCES 
 
1. Suri S, Heise V, Trachtenberg AJ, Mackay CE. The 
forgotten APOE allele: a review of the evidence and 
suggested mechanisms for the protective effect of 
APOE ɛ2. Neurosci Biobehav Rev. 2013; 37:2878–86. 
 https://doi.org/10.1016/j.neubiorev.2013.10.010 
 PMID:24183852 
2. Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E 
- a multifunctional protein with implications in various 
pathologies as a result of its structural features. 
Comput Struct Biotechnol J. 2017; 15:359–65. 
 https://doi.org/10.1016/j.csbj.2017.05.003 
 PMID:28660014 
3. Belloy ME, Napolioni V, Greicius MD. A quarter century 
of APOE and alzheimer’s disease: progress to date and 
the path forward. Neuron. 2019; 101:820–38. 
 https://doi.org/10.1016/j.neuron.2019.01.056 
 PMID:30844401 
4. Eichner JE, Dunn ST, Perveen G, Thompson DM, 
Stewart KE, Stroehla BC. Apolipoprotein E 
polymorphism and cardiovascular disease: a HuGE 
review. Am J Epidemiol. 2002; 155:487–95. 
 https://doi.org/10.1093/aje/155.6.487 
 PMID:11882522 
5. Huebbe P, Rimbach G. Evolution of human 
apolipoprotein E (APOE) isoforms: gene structure, 
protein function and interaction with dietary factors. 
Ageing Res Rev. 2017; 37:146–61. 
 https://doi.org/10.1016/j.arr.2017.06.002 
 PMID:28647612 
6. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, 
Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van 
Duijn CM. Effects of age, sex, and ethnicity on the 
association between apolipoprotein E genotype and 
Alzheimer disease. A meta-analysis. APOE and 
Alzheimer Disease Meta Analysis Consortium. JAMA. 
1997; 278:1349–56. 
 PMID:9343467 
7. Wolters FJ, Yang Q, Biggs ML, Jakobsdottir J, Li S, Evans 
DS, Bis JC, Harris TB, Vasan RS, Zilhao NR, Ghanbari M, 
Ikram MA, Launer L, et al, and E2-CHARGE 
investigators. The impact of APOE genotype on 
survival: results of 38,537 participants from six 
population-based cohorts (E2-CHARGE). PLoS One. 
2019; 14:e0219668. 
 https://doi.org/10.1371/journal.pone.0219668 
 PMID:31356640 
8. Abondio P, Sazzini M, Garagnani P, Boattini A, Monti D, 
Franceschi C, Luiselli D, Giuliani C. The genetic 
variability of APOE in different human populations and 
its implications for longevity. Genes (Basel). 2019; 
10:222. 
 https://doi.org/10.3390/genes10030222 
 PMID:30884759 
9. Deelen J, Evans DS, Arking DE, Tesi N, Nygaard M, Liu X, 
Wojczynski MK, Biggs ML, van der Spek A, Atzmon G, 
Ware EB, Sarnowski C, Smith AV, et al. A meta-analysis 
of genome-wide association studies identifies multiple 
longevity genes. Nat Commun. 2019; 10:3669. 
 https://doi.org/10.1038/s41467-019-11558-2 
 PMID:31413261 
 
www.aging-us.com 12231 AGING 
10. Klaver CC, Kliffen M, van Duijn CM, Hofman A, Cruts M, 
Grobbee DE, van Broeckhoven C, de Jong PT. Genetic 
association of apolipoprotein E with age-related 
macular degeneration. Am J Hum Genet. 1998; 
63:200–6. 
 https://doi.org/10.1086/301901 
 PMID:9634502 
11. McKay GJ, Patterson CC, Chakravarthy U, Dasari S, 
Klaver CC, Vingerling JR, Ho L, de Jong PT, Fletcher AE, 
Young IS, Seland JH, Rahu M, Soubrane G, et al. 
Evidence of association of APOE with age-related 
macular degeneration: a pooled analysis of 15 studies. 
Hum Mutat. 2011; 32:1407–16. 
 https://doi.org/10.1002/humu.21577 
 PMID:21882290 
12. Liberopoulos E, Siamopoulos K, Elisaf M. 
Apolipoprotein E and Renal Disease. Am J Kidney Dis. 
2004; 43:223–33. 
 https://doi.org/10.1053/j.ajkd.2003.10.013 
 PMID:14750087 
13. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, 
Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, 
Whittaker JC, Sanseau P. The support of human genetic 
evidence for approved drug indications. Nat Genet. 
2015; 47:856–60. 
 https://doi.org/10.1038/ng.3314 
 PMID:26121088 
14. Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo 
AM, Epel ES, Franceschi C, Lithgow GJ, Morimoto RI, 
Pessin JE, Rando TA, Richardson A, Schadt EE, et al. 
Geroscience: linking aging to chronic disease. Cell. 
2014; 159:709–13. 
 https://doi.org/10.1016/j.cell.2014.10.039 
 PMID:25417146 
15. Sebastiani P, Gurinovich A, Bae H, Andersen S, Malovini 
A, Atzmon G, Villa F, Kraja AT, Ben-Avraham D, Barzilai 
N, Puca A, Perls TT. Four genome-wide association 
studies identify new extreme longevity variants. J 
Gerontol A Biol Sci Med Sci. 2017; 72:1453–64. 
 https://doi.org/10.1093/gerona/glx027 
 PMID:28329165 
16. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, 
Lanktree MB, Nelson CP, Dale CE, Padmanabhan S, 
Finan C, Swerdlow DI, Tragante V, van Iperen EP, 
Sivapalaratnam S, et al, and UCLEB consortium. 
Mendelian randomization of blood lipids for coronary 
heart disease. Eur Heart J. 2015; 36:539–50. 
 https://doi.org/10.1093/eurheartj/eht571 
 PMID:24474739 
17. Burgess S, Ference BA, Staley JR, Freitag DF, Mason 
AM, Nielsen SF, Willeit P, Young R, Surendran P, 
Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, et al, 
and European Prospective Investigation Into Cancer, 
and Nutrition–Cardiovascular Disease (EPIC-CVD) 
Consortium. Association of LPA variants with risk of 
coronary disease and the implications for 
lipoprotein(a)-lowering therapies: a mendelian 
randomization analysis. JAMA Cardiol. 2018; 3:619–27. 
 https://doi.org/10.1001/jamacardio.2018.1470 
 PMID:29926099 
18. Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, 
Mead D, Bouman H, Riveros-Mckay F, Kostadima MA, 
Lambourne JJ, Sivapalaratnam S, Downes K, et al. The 
allelic landscape of human blood cell trait variation and 
links to common complex disease. Cell. 2016; 
167:1415–29.e19. 
 https://doi.org/10.1016/j.cell.2016.10.042 
 PMID:27863252 
19. Calabrò P, Gragnano F, Pirro M. Cognitive function in a 
randomized trial of evolocumab. N Engl J Med. 2017; 
377:1996–7. 
 https://doi.org/10.1056/NEJMc1712102 
 PMID:29143516 
20. Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybjærg-
Hansen A. Low LDL cholesterol, PCSK9 and HMGCR 
genetic variation, and risk of Alzheimer’s disease and 
Parkinson’s disease: Mendelian randomisation study. 
BMJ. 2017; 357:j1648. 
 https://doi.org/10.1136/bmj.j1648 
 PMID:28438747 
21. Reiman EM, Arboleda-Velasquez JF, Quiroz YT, 
Huentelman MJ, Beach TG, Caselli RJ, Chen Y, Su Y, 
Myers AJ, Hardy J, Paul Vonsattel J, Younkin SG, 
Bennett DA, et al, and Alzheimer’s Disease Genetics 
Consortium. Exceptionally low likelihood of alzheimer’s 
dementia in APOE2 homozygotes from a 5,000-person 
neuropathological study. Nat Commun. 2020; 11:667. 
 https://doi.org/10.1038/s41467-019-14279-8 
 PMID:32015339 
22. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey 
Smith G. Collider scope: when selection bias can 
substantially influence observed associations. Int J 
Epidemiol. 2018; 47:226–35. 
 https://doi.org/10.1093/ije/dyx206 
 PMID:29040562 
23. Magder LS, Hughes JP. Logistic regression when the 
outcome is measured with uncertainty. Am J 
Epidemiol. 1997; 146:195–203. 
 https://doi.org/10.1093/oxfordjournals.aje.a009251 
 PMID:9230782 
24. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, 
Danesh J, Downey P, Elliott P, Green J, Landray M, Liu 
B, Matthews P, Ong G, et al. UK biobank: an open 
access resource for identifying the causes of a wide 
range of complex diseases of middle and old age. PLoS 
Med. 2015; 12:e1001779. 
 
www.aging-us.com 12232 AGING 
 https://doi.org/10.1371/journal.pmed.1001779 
 PMID:25826379 
25. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, 
Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell 
J, Cortes A, Welsh S, Young A, et al. The UK biobank 
resource with deep phenotyping and genomic data. 
Nature. 2018; 562:203–09. 
 https://doi.org/10.1038/s41586-018-0579-z 
 PMID:30305743 
26. Thompson WD, Tyrrell J, Borges MC, Beaumont RN, 
Knight BA, Wood AR, Ring SM, Hattersley AT, Freathy 
RM, Lawlor DA. Association of maternal circulating 
25(OH)D and calcium with birth weight: a mendelian 
randomisation analysis. PLoS Med. 2019; 16:e1002828. 
 https://doi.org/10.1371/journal.pmed.1002828 
 PMID:31211782 
27. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, 
Chen WM. Robust relationship inference in genome-
wide association studies. Bioinformatics. 2010; 
26:2867–73. 
 https://doi.org/10.1093/bioinformatics/btq559 
 PMID:20926424 
28. Sheard SM, Nicholls R, Froggatt J. UK Biobank 
Haematology Data Companion Document. 2017. 
https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/hae
matology.pdf 
29. UK Biobank biomarker panel.  
 http://www.ukbiobank.ac.uk/wp-content/uploads/ 
2013/12/ukb_biomarker_panel_final_website_Oct201
3_CLMS.pdf 
30. Williams DM, Jylhävä J, Pedersen NL, Hägg S. A frailty 
index for UK biobank participants. J Gerontol A Biol Sci 
Med Sci. 2019; 74:582–87. 
 https://doi.org/10.1093/gerona/gly094 
 PMID:29924297 
31. Janssen I, Heymsfield SB, Baumgartner RN, Ross R. 
Estimation of skeletal muscle mass by bioelectrical 
impedance analysis. J Appl Physiol (1985). 2000; 
89:465–71. 
 https://doi.org/10.1152/jappl.2000.89.2.465 
 PMID:10926627 
32. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, 
Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, 
McBurnie MA, and Cardiovascular Health Study 
Collaborative Research Group. Frailty in older adults: 
evidence for a phenotype. J Gerontol A Biol Sci Med 
Sci. 2001; 56:M146–56. 
 https://doi.org/10.1093/gerona/56.3.m146 
 PMID:11253156 
33. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth 
ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis 
JF, Oja P. International physical activity questionnaire: 
12-country reliability and validity. Med Sci Sports 
Exerc. 2003; 35:1381–95. 
 https://doi.org/10.1249/01.MSS.0000078924.61453.FB 
 PMID:12900694 
  
 
www.aging-us.com 12233 AGING 
SUPPLEMENTARY MATERIALS 
 
 
 
Supplementary Tables 
 
Please browse Full Text version to see the data of Supplementary Tables 1, 2. 
 
Supplementary Table 1. A summary of aging traits for the ApoE genotypes separately. 
 
Supplementary Table 2. Associations between the ApoE genotypes and aging traits. 
 
Supplementary Table 3. ICD-10 disease codes. 
Disease ICD-10 codes Notes 
Age-Related Macular Degeneration H353  
Anemia D50-D53  
Atrial Fibrillation I48  
Bladder Cancer C67  
Breast Cancer C50  
Colorectal Cancer C18-20  
COPD J42-J44  
Delirium F05  
Dementia F00; F01; F02; F03; G30  
Heart Failure I50; J81  
Hypertension I10-I15  
Hypothyroidism E03  
Liver Disease K70-K77 Any 
Lung Cancer C34  
Melanoma Cancer C43 Malignant Melanoma 
Coronary Artery Disease I20–I25 MI or Angina 
Osteoarthritis M15.0; M15.1; M15.2; M15.9; M16.0; M16.1; M17.0; 
M17.1; M18.0; M18.1; M19.0 
 
Osteoporosis M80; M81; M81.1; M81.2; M81.3; M81.4; M81.5; 
M81.6; M81.8; M81.9 
 
Parkinson's Disease G20; F02.3  
Peripheral Artery Disease I70.2; I70.9; I73; I74.2; I74.3; I74.4; I74.5; I79.2 Peripheral Vascular Disease 
Pneumonia J13; J14; J15; J16; J17; J18  
Prostate Cancer C61  
Renal Failure N18; N18.0; N18.3; N18.4; N18.5; N18.8; N18.9  
Rheumatoid Arthritis M05; M06  
Stoke G45-G46; I61; I63 Stroke/TIA 
Type I Diabetes E10  
Type II Diabetes E11  
 
